

Phase I Trial: Quotient Code QSC303217

Submission date 24/06/2025	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 01/07/2025	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 01/07/2025	Condition category Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Public, Scientific

Contact name

Dr Terrie Kellmeyer

Contact details

Aardvark Therapeutics, Inc., 4370 La Jolla Village Drive, Suite 1050
San Diego
United States of America
92122
+1 (858) 225-7696
Info@AardvarkTherapeutics.com

Type(s)

Principal investigator

Contact name

Dr David Everton

Contact details

Quotient Sciences Limited, Mere Way, Ruddington Fields, Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)330 303 1000
recruitment@weneedyou.co.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

1011885

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Sponsor Code: AVK-101-102, Quotient Code: QSC303217

Study information

Scientific Title

Phase I Trial: Quotient Code QSC303217

Study objectives

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 19/06/2025, London – Hampstead Regulatory Ethics Committee (REC) (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)20 7104 8171; hampstead.rec@hra.nhs.uk), ref: 25/LO/0198

Study design

Two-part single-centre mass balance recovery and food effect study in healthy volunteers

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Interventions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Completion date

22/08/2025

Eligibility

Key inclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

65 years

Sex

All

Key exclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

01/07/2025

Date of final enrolment

22/08/2025

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre**Quotient Sciences Limited**

Mere Way, Ruddington Fields, Ruddington

Nottingham

United Kingdom

NG11 6JS

Sponsor information**Organisation**

Aardvark Therapeutics, Inc.

Funder(s)**Funder type**

Industry

Funder Name

Aardvark Therapeutics, Inc.

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available